Both MAGE-C1 and NY-ESO-1 are frequently expressed in MM (66% and 22% of cases respectively), with 93% of MAGE-C1-positive myelomas eliciting a detectable humoral and cellular immune response against this antigen [65,66]. This evidence concerns the gene MAGEC1 and Miyoshi myopathy.